Quick Answer
AIM ImmunoTech Inc. reported Operating Income Loss of -$11.66 million for the year ending 2025.
- AIM ImmunoTech Inc. showed an increase of +41.0% in Operating Income Loss from 2024 to 2025.
- This data is from AIM ImmunoTech Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), AIM ImmunoTech Inc.'s Operating Income Loss has grown by 12.1%.
- Historical annual values: Fiscal year 2025: -$11.66 million | Fiscal year 2024: -$19.77 million | Fiscal year 2023: -$31.92 million | Fiscal year 2022: -$19.92 million | Fiscal year 2021: -$18.84 million | Fiscal year 2020: -$15.15 million | Fiscal year 2019: -$12.44 million | Fiscal year 2018: -$11.50 million | Fiscal year 2017: -$11.42 million | Fiscal year 2016: -$13.80 million | Fiscal year 2015: -$16.65 million | Fiscal year 2014: -$19.10 million | Fiscal year 2013: -$17.17 million | Fiscal year 2012: -$20.34 million | Fiscal year 2011: -$14.30 million | Fiscal year 2010: -$16.39 million | Fiscal year 2009: -$13.26 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: